title: Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
authors.affiliation: Henry Ford Hospital, Detroit, MI 48202.
authors.forename: M F
authors.initials: MF
authors.lastname: Mozes
authors.forename: K K
authors.initials: KK
authors.lastname: Venkat
authors.forename: W
authors.initials: W
authors.lastname: Kupin
authors.forename: F
authors.initials: F
authors.lastname: Dumler
authors.forename: C
authors.initials: C
authors.lastname: Gracida
authors.forename: M
authors.initials: M
authors.lastname: Uniewski
authors.forename: D
authors.initials: D
authors.lastname: Anaise
authors.forename: D H
authors.initials: DH
authors.lastname: Tang
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology*; D007902:Length of Stay; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D008775:Methylprednisolone